T issue factor (TF) is the principal initiator of blood clotting in response to vascular injury and in thrombotic disease (1) . TF, an integral membrane protein, is normally excluded from the vascular compartment. Coagulation is initiated when TF is exposed to zymogen coagulation proteases in plasma upon vascular damage. TF first binds factor VII, supporting both its activation to VIIa and activation of factor X (Fig. 1) . Factor Xa acts with its cellular cofactor Va to generate thrombin (IIa), which drives both fibrin deposition and platelet aggregation. Thrombin elicits signaling in cells through protease-activated receptors (PARs), a family of G proteincoupled receptors, which are activated proteolytically by unmasking of an Nterminal tethered ligand ( Fig. 1) (2) . In addition to hemostasis, TF expression and coagulant protease activation have been implicated in inflammation, vascular development, and cancer progression. Signaling by coagulant proteases is an important consequence of TF exposure in these settings. Factors VIIa and Xa have been shown to cleave and activate PAR2, the only PAR not activated by thrombin, and may act in concert with thrombin to elicit cellular responses to coagulation activation (Fig. 1) . VIIa requires its cofactor TF to facilitate PAR2 cleavage and activation. The molecular determinants that specify TF function as a cofactor for cellular signaling versus coagulation are not known. In a recent issue of PNAS, Ahamed et al. (3) provide fascinating insight suggesting that coagulant and signaling TF may, in fact, be two different structural entities, that signaling TF may be the long-elusive encrypted TF, and that disulfide isomerization facilitates a dynamic and reversible switch between these two distinct functional TF species.
TF encryption has been widely studied in cell culture and may represent a physiological mechanism for controlling expression of cellular coagulant activity in vivo. Recent reports suggest the existence of circulating TF important for clot propagation that only becomes active in the context of a growing thrombus (4) . Cells that constitutively express TF also display latent forms of this protein. Although there is usually good correlation between cell surface TF expression and binding and allosteric activation of VIIa, the ability of this complex to activate X is variable and usually attributable to only a fraction of the TF:VIIa complexes formed (5, 6) . The TF population unable to promote coagulation has been dubbed ''encrypted.'' When cells are damaged, lysed by cycles of freeze-thawing, or treated with certain cell-activating agents such as calcium ionophores, coagulant potential is dramatically increased. One prevailing model for induction of TF activity was the exposure of phosphatidylserine on the outer leaflet of the plasma membrane, because negatively charged lipids are limiting and required for optimal TF:VIIa activity toward factor X. TF dimerization and͞or compartmentalization in lipid rafts such as caveolae might also limit enzymatic activity. The studies by Ahamed et al. (3) now suggest a new mechanism for modulating TF coagulant activity involving conformational changes induced by disulfide bond cleavage.
Disulfide bond rearrangements can function as an allosteric mechanism to regulate protein function, as demonstrated for several cell surface proteins including CD4 and integrins (7) . Protein disulfide isomerase (PDI) is capable of catalyzing all of the reactions involved in disulfide bond formation, cleavage, and isomerization (rearrangements) (8) . PDI facilitates folding of nascent proteins in the endoplasmic reticulum but also resides on the surface of mammalian cells and platelets. PDI has been shown to cleave disulfide bonds in the extracellular domains of certain receptors to allosterically regulate protein activity. Interestingly, PDI readily cleaves rare disulfide bonds in which high strain is introduced by linking strands in the same or parallel ␤-sheets (7). TF disulfide-bonded Cys 186 and Cys 209 link two parallel ␤-sheets, are required for coagulation (9), and were predicted to function in allosteric modulation of TF function (7, 10 To what extent does the noncoagulant TF shown to associate with PDI account for encrypted TF? Because coagulant and PDI reduced TF appear to come from the same small pool of cell surface TF, is the main fraction of encrypted TF still unaccounted for by this new mechanism? Previous studies have shown that certain cellular perturbations or cell-activating agents induce TF coagulant activity (6) . The authors might have addressed whether induction of TF coagulant activity by such cellular activators also released TF from a complex with PDI. At present, it remains unclear whether the distinct form of noncoagulant TF identified by Ahamed et al. (3) truly represents encrypted TF or whether it coexists with other latent forms of TF that are regulated by other mechanisms. As shown by Ahamed et al., TF can be further modified by S-nitrosylation and perhaps glutathionation, suggesting that these uniquely modified TF forms might also represent physiological encrypted forms of TF.
The second key finding by Ahamed et al. (3) is that disulfide bond cleavage stabilizes a distinct noncoagulant form of TF that specifically signals through PAR2. VIIa activates PAR2 either directly in a binary complex with TF or indirectly by generation of Xa, which can activate both PAR2 and PAR1 (Fig. 1) (11) . Xa may signal more efficiently in a ternary complex with TF:VIIa than it does as a monomer (12). Ahamed et al. now propose that binary signaling involves a distinct form of TF identical to the cryptic TF generated by PDI isomerase switching. A Cys 209 -toAla substitution in TF blunted its ability to support X activation and Xa signaling but did not diminish VIIa signaling. Signaling TF and PAR2 were shown to associate with PDI on the cell surface, and PDI activity promoted VIIa signaling. These findings were corroborated by the use of a specific TF antibody that recognized only the noncoagulant form of TF, suggesting that signaling TF has a distinct conformation. The existence of TF:PAR2 complex poised for signaling not only advocates a physiological role for VIIa signaling but also suggests that VIIa is a relevant physiological activator of PAR2, a receptor that is not fully deorphanized. A cryptic TF:VIIa signaling complex may also have a distinct advantage over signaling by other coagulant proteases in relative protection from inhibitors. Thrombin, the most potent PAR activator, is efficiently inhibited by antithrombin III, and thrombomodulin competes with PAR1 for thrombin binding on the endothelial cell surface. Xa is also inhibited by antithrombin III as well as by TF pathway inhibitor. The only effective inhibitor of VIIa is TF pathway inhibitor when bound to Xa (13) . Because cryptic TF is defective in Xa binding, it is likely protected from this inhibition.
Why would both coagulant TF:VIIa:Xa and noncoagulant TF:VIIa activate PAR2? Have two distinct but near identical signaling complexes truly evolved to compete for the same receptor on the same cell, or are monomeric Xa and thrombin the signaling entities of coagulant TF? The findings of Ahamed et al. (3) raise the intriguing question of whether binary TF:VIIa has a distinct function, possibly dictated by interactions between cofactor TF and PAR2. It is possible that activation of PAR2 by coagulant versus noncoagulant TF induces distinct cellular responses. PAR2 couples to G q , G i , and perhaps G 12/13 as well as non-G protein effectors, such as arrestins, that function as scaffolds for MAP kinase signaling cascades. Thus, the possibility that distinct conformations of activated PAR2 might specify coupling to different signaling effectors is intriguing and raises questions regarding the nature of the complex. Is PDI able to bridge the interaction between TF and PAR2, or is there a direct TF:PAR2 interaction? Ruf and colleagues (14, 15) have suggested another regulatory switch whereby TF cytoplasmic tail phosphorylation promotes PAR2 signaling and simultaneously releases TF from a complex with integrins. How does PDI and TF disulfide switching fit with this model? A switch between a coagulant and a signaling form of TF might imply that a separation between these functions is desirable. Most proposed functions for coagulation protease signaling are proinflammatory, and signaling has been thought to complement coagulation in fending off pathogens and in recruitment of immune cells to sites of injury. Emerging evidence suggests that PARs can also act as guardians of a challenged vascular endothelium (16, 17) . Might signaling functions of cryptic and coagulant TF be distinct, e.g., with binary TF:VIIa:PAR2 signaling of a protective nature analogous to activation of PAR1 by activated protein C and ternary or monomeric Xa-or thrombin-induced PAR signaling mostly proinflammatory? Finally, Ahamed et al. propose signaling TF as a possible drug target; epitopes unique to the complex may allow targeting of TF:VIIa signaling without affecting coagulation. Because it is unclear whether a scenario would ever exist in vivo where only TF:VIIa were active without concomitant Xa generation and Xa͞thrombin-mediated PAR signaling, this approach needs validation. Perhaps the unique features provided by the cryptic TF signaling complex, such as protection from protease inhibitors or distinct cellular signaling, provide advantages that obviate this caveat. Clearly, there is more to learn about TF regulation and function both biochemically and in vivo. The study by Ahamed et al. has shed light on a potentially important mechanism for regulation of TF activity and will undoubtedly spark interest.
